StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$13.04−0.46 (-3.41%)

Close on Nov 17, 2026Market cap $484.36MP/E –Yield –

Crescent Biopharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Crescent Biopharma's enterprise value was $237.95M on Nov 11, 2026, against $75.82M a year earlier. Over the last 5 years it ranged from -$35.77K to $19.28B, with a median of $2.62B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$237.95M+655.4%
2025Dec 31, 2025$31.50M-98.0%
2024Dec 31, 2024$1.61B-89.4%
2023Dec 29, 2023$15.14B-4.4%
2022Dec 30, 2022$15.83B+115.5%
2021Dec 31, 2021$7.35B-58.8%
2020Dec 31, 2020$17.84B-21.6%
2019Dec 31, 2019$22.77B-44.0%
2018Dec 31, 2018$40.63B-25.9%
2017Dec 29, 2017$54.85B+291.2%
2016Dec 30, 2016$14.02B+29.4%
2015Dec 31, 2015$10.84B-20.0%
2014Dec 31, 2014$13.54B–

More Crescent Biopharma figures

See a number that looks wrong?